Clinical and Molecular Hepatology (Mar 2016)

Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C

  • Jong Wook Choi,
  • June Sung Lee,
  • Woo Hyun Paik,
  • Tae Jun Song,
  • Jung Wook Kim,
  • Won Ki Bae,
  • Kyung-Ah Kim,
  • Jung Gon Kim

DOI
https://doi.org/10.3350/cmh.2016.22.1.168
Journal volume & issue
Vol. 22, no. 1
pp. 168 – 171

Abstract

Read online

Chronic hepatitis C virus (HCV) infection is a major cause of liver cirrhosis and hepatocellular carcinoma. Combination therapy of pegylated interferon-alpha (PEG-IFN-α) and ribavirin (RBV) is a current standard treatment for chronic HCV infection in Korea, which has considerable adverse effects. Acute pancreatitis is a rare complication of PEG-IFN-α administration. We report a case of a 62-year-old female who experienced acute pancreatitis after 4 weeks of PEG-IFN-α-2a and RBV combination therapy for chronic HCV infection. The main cause of the acute pancreatitis in this case was probably PEG-IFN-α rather than RBV for several reasons. A few cases have been reported in which acute pancreatitis occurred during treatment with PEG-IFN-α-2b. This is the first report of acute pancreatitis associated with PEG-IFN-α-2a in Korea.

Keywords